Novo Nordisk just took another step toward a potential kick-start for its newest basal insulin, Tresiba.

In the immuno-oncology rivalry between Merck’s Keytruda and BMS’ Opdivo, Keytruda has been running the table. But Opdivo boasts the latest win.

Novo Nordisk has moved to settle a whistleblower lawsuit alleging the company ran a “white-coat marketing scheme” to pump up sales of NovoLog, Victoza and…

Massachusetts-based Radius Health scored an early approval Friday for Tymlos, an osteoporosis treatment for postmenopausal women. But to succeed with the drug…

Kim Kardashian is back on social media plugging for pharma. This time, the FDA might like her Instagram post better, but Instagram followers weren't so…

Pfizer's Xeljanz is an obvious beneficiary of Eli Lilly's surprise Olumiant (baricitinib) rejection at the FDA. But AbbVie and Gilead could gain, too.

Pharma has come a long way on patient centricity. Regulators, though? Not so much, Treato's CEO says.

While some analysts aren’t thrilled by Allergan's phase 2 data for Botox in depression, the company sees enough promise to move the therapy into a wide…